Palvella Therapeutics (PVLA) Q4 2025 earnings summary

Executive summary

• Achieved major milestones in 2025, including positive Phase III SELVA results for QTORIN rapamycin in microcystic lymphatic malformations, meeting all endpoints and expanding the pipeline into new indications such as angiokeratomas and DSAP.

• Surpassed enrollment targets in key studies, secured multiple FDA designations (Breakthrough, Fast Track, Orphan Drug), and accelerated U.S. launch readiness for QTORIN rapamycin, targeting first FDA approval in H1 2027.

• Strengthened leadership team with key hires in market access and human resources, and extended FDA collaboration, including non-dilutive funding.

• Raised $230 million in an oversubscribed public offering, providing a strong cash position to fund development and launch activities.

• Focused on first-in-disease therapies for rare skin diseases with high unmet need and no approved therapies.

Financial highlights

• Ended Q4 2025 with $58 million in cash and equivalents; pro forma cash of $274 million as of December 31, 2025, after $230 million public offering in February 2026.

• Net proceeds from the offering were $215.8 million.

• Research and development expenses rose to $22.8 million for 2025, and general and administrative expenses increased to $15.8 million.

• Net loss attributable to common stockholders was $41.7 million ($3.71 per share) for 2025.

• 2026 cash burn expected to be around $80 million, with pro forma cash fully funding lead programs through NDA filing, potential approval, and launch.

Outlook and guidance

• NDA submission for QTORIN rapamycin in microcystic lymphatic malformations targeted for H2 2026, with potential FDA approval in H1 2027.

• Phase III study for cutaneous venous malformations to initiate in H2 2026, pending Breakthrough Therapy designation.

• Phase II studies for angiokeratomas and DSAP scheduled for 2026, with angiokeratomas study beginning in Q2 2026 ahead of schedule.

• Two new pipeline programs expected to be announced in H2 2026.